Literature DB >> 7742009

The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.

D R Fitzpatrick1, D J Peroni, H Bielefeldt-Ohmann.   

Abstract

Malignant mesothelioma (MM) is an asbestos-associated cancer that is increasing in incidence worldwide and is refractory to conventional therapy. MM cells are potent sources of a number of cytokines, some of which have recently been shown to be directly involved in the aggressive growth and spread of MM tumors. Emerging data also suggest involvement of MM-derived cytokines in systemic paraneoplastic syndromes including immunosuppression, thrombocytosis, cachexia, amyloidosis, and hypoglycemia. Additional characterization of the expression of cytokines and cytokine receptors in situ in MM tumors may provide a more complete picture of the autocrine and paracrine processes which occur in MM. Improved therapy of MM, particularly cytokine-based approaches, is likely to benefit from further elucidation of the patterns and regulation of cytokine expression associated with MM tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742009     DOI: 10.1165/ajrcmb.12.5.7742009

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  11 in total

1.  Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.

Authors:  Shuko Murakami; Yasumitsu Nishimura; Megumi Maeda; Naoko Kumagai; Hiroaki Hayashi; Ying Chen; Masayasu Kusaka; Takumi Kishimoto; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2009-03-18       Impact factor: 3.674

Review 2.  Serum mesothelin and other biomarkers: what have we learned in the last decade?

Authors:  Alfonso Cristaudo; Alessandra Bonotti; Giovanni Guglielmi; Poupak Fallahi; Rudy Foddis
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.

Authors:  Arti Shukla; Trisha F Barrett; Maximilian B MacPherson; Jedd M Hillegass; Naomi K Fukagawa; William A Swain; Kenneth J O'Byrne; Joseph R Testa; Harvey I Pass; Stephen P Faux; Brooke T Mossman
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-31       Impact factor: 6.914

4.  Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology.

Authors:  P Harvey; A Warn; S Dobbin; N Arakaki; Y Daikuhara; M C Jaurand; R M Warn
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

Review 5.  Peritoneal mesothelioma.

Authors:  R N Taub; M L Keohan; J C Chabot; K S Fountain; M Plitsas
Journal:  Curr Treat Options Oncol       Date:  2000-10

6.  Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma.

Authors:  Nathan R Miselis; Bonnie W Lau; Zhijin Wu; Agnes B Kane
Journal:  Cancer Microenviron       Date:  2010-06-22

7.  Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.

Authors:  R Mendes; M E R O'Brien; A Mitra; A Norton; R K Gregory; A R Padhani; K V Bromelow; A R Winkley; S Ashley; I E Smith; B E Souberbielle
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

8.  Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.

Authors:  James P Stevenson; Hedy L Kindler; Emmanouil Papasavvas; Jing Sun; Mona Jacobs-Small; Jennifer Hull; Daniel Schwed; Anjana Ranganathan; Kheng Newick; Daniel F Heitjan; Corey J Langer; John M McPherson; Luis J Montaner; Steven M Albelda
Journal:  Oncoimmunology       Date:  2013-08-27       Impact factor: 8.110

9.  The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.

Authors:  C E Hooper; I D Lyburn; J Searle; M Darby; T Hall; D Hall; A Morley; P White; N M Rahman; E De Winton; A Clive; V Masani; D T Arnold; A Dangoor; S Guglani; P Jankowska; S A Lowndes; J E Harvey; J P Braybrooke; N A Maskell
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

10.  Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.

Authors:  Chang Li; Veronika Rezov; Emmi Joensuu; Ville Vartiainen; Mikko Rönty; Miao Yin; Marjukka Myllärniemi; Katri Koli
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.